TrialSignal transduction and targeted therapy2026
Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.
Jia Yu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.